10:13 AM EST - Theratechnologies Inc. : Presented preclinical data that demonstrate the potential utility of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902) -- both as a single agent and in combination with other anticancer therapies -- in targeting tumors that express the sortilin (SORT1) receptor. The new data were presented in poster sessions at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Fla. Theratechnologies Inc.
shares T.TH are trading up $0.05 at $1.30.
